2017
Improving correctional healthcare providers' ability to care for transgender patients: Development and evaluation of a theory-driven cultural and clinical competence intervention
Hughto J, Clark KA, Altice FL, Reisner SL, Kershaw TS, Pachankis JE. Improving correctional healthcare providers' ability to care for transgender patients: Development and evaluation of a theory-driven cultural and clinical competence intervention. Social Science & Medicine 2017, 195: 159-169. PMID: 29096945, PMCID: PMC5712271, DOI: 10.1016/j.socscimed.2017.10.004.Peer-Reviewed Original ResearchConceptsCorrectional healthcare providersGender-affirming careTransgender patientsHealthcare providersClinical competenceTransgender careTransgender cultural competenceFuture efficacy testingLinear mixed-effects regression modelsHealthcare providers' abilityQualitative exit interviewsMixed effects regression modelsGroup-based interventionHormone therapyPatientsProviders' willingnessTransgender womenStudy outcomesExit interviewsCareEfficacy testingInterventionProviders' abilityEffects regression modelsConfidential surveyImplementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes
Mazhnaya A, Meteliuk A, Barnard T, Zelenev A, Filippovych S, Altice FL. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes. International Journal Of Drug Policy 2017, 47: 187-195. PMID: 28811159, PMCID: PMC5918282, DOI: 10.1016/j.drugpo.2017.07.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsCoinfectionFemaleGenotypeHealth ServicesHepacivirusHepatitis CHIV InfectionsHumansInterferon-alphaMalePolyethylene GlycolsProgram DevelopmentProgram EvaluationRecombinant ProteinsRibavirinRisk FactorsSex FactorsSofosbuvirSubstance Abuse, IntravenousSustained Virologic ResponseTreatment OutcomeUkraineYoung AdultConceptsSustained virologic responseHCV treatmentRisk groupsSVR ratesMedical recordsDirect acting antiviral medicationsComparable SVR ratesHCV genotype 3HCV prevalence estimatesHCV treatment servicesActing antiviral (DAA) medicationsCombination of sofosbuvirHigh-risk groupPatient-level outcomesProportion of participantsCommunity-based settingsDAA treatmentVirologic responseAntiviral medicationsHIV characteristicsHCV genotypesIndependent correlatesSVR dataFemale sexGenotype 3
2007
Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services
Sylla L, Bruce RD, Kamarulzaman A, Altice FL. Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. International Journal Of Drug Policy 2007, 18: 306-312. PMID: 17689379, PMCID: PMC2696234, DOI: 10.1016/j.drugpo.2007.03.001.Peer-Reviewed Original ResearchConceptsInjection drug useSubstance use treatmentDrug usersEffective substance use treatmentTraining Community Health WorkersActive injection drug useUse treatmentIntegrated care delivery systemSpecialist care providersAdverse drug eventsCommunity health workersComplex patient populationInjection drug usersAdverse side effectsDrug treatment servicesDrug-drug interactionsDetection of tuberculosisCare delivery systemHIV/AIDSAntiretroviral medicationsMedication adherencePatient populationDrug eventsHIV epidemicHealth workersHIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine—programme description and policy implications
Bruce RD, Dvoryak S, Sylla L, Altice FL. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine—programme description and policy implications. International Journal Of Drug Policy 2007, 18: 326-328. PMID: 17689382, PMCID: PMC2084072, DOI: 10.1016/j.drugpo.2006.12.011.Peer-Reviewed Original ResearchConceptsBuprenorphine maintenance therapyInjection drug useAnti-retroviral therapySubstitution therapyDrug useAddition of methadoneAdministration of buprenorphineHIV-1 seropositivityOpiate substitution therapyOverall health outcomesIllicit drug useCost of buprenorphineHIV treatment accessMaintenance therapyOpioid dependenceHIV casesEntry criteriaTreatment accessBuprenorphineDrug usersHealth outcomesMultidisciplinary teamTherapyGlobal Fund resourcesAdministration